Top Tweets for #CorcoranLab
@SGO_org Although not in ovarian cancer, resistance mechanisms to rezatapopt have already been reported by @FerranFeceCruz and @AndreasVarkaris. An important paper to keep in mind as rezatapopt moves forward. @MassGenBrigham @harvardmed #CorcoranLab
https://t.co/Cd3IjVaG4k #SGOAM26
Grateful for an amazing 3 weeks at the Termeer Center, @MGHMedicine @MGHCancerCenter!
Special thanks to Dr. @AndreasVarkaris for the fantastic mentorship. I was especially inspired by the seamless collaboration between the lab and the clinic! #CorcoranLab @FerranFeceCruz
Want to know what's next on targeting (K)RAS? Look no further, this is your review! Congrats Jakob Riedl & Hiro Matsubara #CorcoranLab @Cancer_Cell @MGHCancerCenter @MassGeneralNews @KRASKickers #KRAS @oncodaily @OncoAlert
https://t.co/WELzYDZnnv
Happy to report the first clinical evidence revealing how tumors develop resistance to p53-Y220C reactivators out today @CD_AACR @MassGenBrigham @harvardmed #CorcoranLab #Rezatapopt #p53Y220C #PYNNACLE
https://t.co/6bQBuUgy0d
It has been a pleasure to host Piro Lito @MSKCancerCenter for what has been a mind-blowing seminar on targeting RAS. It's the hydrolysis!!! @MGHCancerCenter #CorcoranLab #KRAS
Getting ready for #AACR25! Very excited to discuss our work on resistance to small molecule reactivators of Y220C-mutant p53. Chicago here we come! @AACR @MGHCancerCenter @harvardmed #CorcoranLab #TP53 #Y220C
Notably, the proportion of patients with ≥1 acquired RAS/MAPK alteration was significantly higher in CRC compared to NSCLC (69% vs. 26%). @Annals_Oncology @MGHCancerCenter #CorcoranLab #crcsm #lcsm
Fresh from the oven @Annals_Oncology, #CorcoranLab reports "Genomic landscape of clinically acquired resistance alterations in patients treated with #KRASG12C inhibitors", a work led by our brilliant Austrian postdoc Jakob Riedl! @MGHCancerCenter @FWF_at
https://t.co/9EBGjaGrKb
Incidence and characterization of TOP1 mutations arising in the setting of ADC resistance in #MBC, and the potential impact on mediating cross-resistance to sequential ADCs! @CCR_AACR @MGHCancerCenter @harvardmed #CorcoranLab #bcsm @BreastCancerNow
https://t.co/ow89uHb5wr
Great presentation at #ESMO24 by our Austrian superstar Dr. Jakob Riedl! Clinical resistance to KRASG12C inhibitors and how to overcome it with new drugs #RM018 #RM042 #CorcoranLab @MGHCancerCenter @harvardmed
Frequency of clinical acquired RAS-MAPK pathway resistance alterations in patients treated with KRASG12C inhibitors: An individual patient meta-analysis #ESMO24
The May issue of Cancer Discovery is now online!
https://t.co/jl5oJEHvBR
On the way to #AACR24! Ready to discuss our work on resistance to PIK3CA inhibitors in breast cancer and beyond! @AACR @MGHCancerCenter @harvardmed #SanDiego #PIK3CA #alpelisib #inavolisib #bcsm #CorcoranLab
Today #CorcoranLab together with @Labrat3 and @andrewaguirremd @DanaFarber presents "One for all and all for one: Repurposing KRASG12C inhibitors to target all RASG12C isoforms"
@MGHCancerCenter @harvardmed @CD_AACR #Sotorasib #NRAS #HRAS #crcsm #GITwitter
https://t.co/pT4CvAc3bp
"Researchers identify the mutations that drive resistance to PI3K inhibitors in breast cancer" @MGHCancerCenter @harvardmed @AndreasVarkaris #CorcoranLab @EurekAlert @agencia_sinc @BreastCancerNow @BreastCaupdates @OncoAlert #bcsm
https://t.co/7icVm3r8ql
Happy to report that we have identified secondary PIK3CA mutations as a novel mechanism of resistance to orthosteric PI3Kα inhibitors in breast cancer patients! @CD_AACR @MGHCancerCenter @harvardmed #CorcoranLab #Alpelisib #Inavolisib #bcsm
https://t.co/kAcRReLGhA
Congrats my colleagues @DrHaleyEllis and @FerranFeceCruz and other people who worked on this project at #BardeesyLab and #CorcoranLab on the potential resistance mechanisms to FGFR inhibitor in FGFR2-dependent #cholangiocarcinoma @MGHCancerCenter
Congrats @DrHaleyEllis and everyone at #BardeesyLab and #CorcoranLab for this tour de force defining the clinical landscape of potential resistance mechanisms to FGFR-i in FGFR2-dependent #cholangiocarcinoma @MGHCancerCenter @harvardmed @CCR_AACR @curecc
https://t.co/hx17Ud12XT
Congrats @DrHaleyEllis and everyone at #BardeesyLab and #CorcoranLab for this tour de force defining the clinical landscape of potential resistance mechanisms to FGFR-i in FGFR2-dependent #cholangiocarcinoma @MGHCancerCenter @harvardmed @CCR_AACR @curecc
https://t.co/hx17Ud12XT
Update on the current status of KRAS-targeting approaches by the boss #CorcoranLab #KRAS @MGHCancerCenter @harvardmed @KRASKickers
https://t.co/X5jPqJRcHH
New work led by Meagan Ryan #CorcoranLab is out on @CellReports providing evidence that reactivation of the RAS-MAPK pathway through wt NRAS/HRAS can drive adaptive resistance to #KRASG12C inh in a KRASG12C-independent manner. Congrats! @MGHCancerCenter
https://t.co/sUBwXtosbv
Work work work 🥳🥳🥳 #CorcoranLab
Congratulations @skopetz @MDAndersonNews who will co-lead a @SU2C Catalyst team with Ryan Corcoran @MGHCancerCenter to identify resistance mechanisms to KRAS G12C inhibitors & potential combination therapies.
Last Seen Hashtags on Sotwe
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.4M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
83.9M followers
Lady Gaga
@ladygaga
75.4M followers
Virat Kohli
@imvkohli
73.3M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.3M followers
Bill Gates
@billgates
65.1M followers
Selena Gomez
@selenagomez
63M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers